Max Healthcare InstituteNSE:MAXHEALTH -1.80%90 EBITDA Margin % is 30.53% as of Mar. 2026, which is 47% above its 10-year median of 20.74. GuruFocus rates NSE:MAXHEALTH with a GF Score™ of 90/100 and a GF Value™ of ₹1,420.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Max Healthcare Institute ranks better than 89.04% on this metric.
Max Healthcare Institute (NSE:MAXHEALTH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Max Healthcare Institute EBITDA Margin % Related Terms
Max Healthcare Institute EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MAXHEALTH vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Max Healthcare Institute's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Max Healthcare Institute EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Max Healthcare Institute's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Max Healthcare Institute's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Max Healthcare Institute (NSE:MAXHEALTH) has a EBITDA Margin % of 30.53% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Max Healthcare Institute and its competitors. This is 47% above median its historical median of 20.74. Over the past decade, Max Healthcare Institute's EBITDA Margin % has ranged from 9.48 to 31.17. According to the industry distribution chart, Max Healthcare Institute ranks #73 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 11%.
Is Max Healthcare Institute's EBITDA Margin % too high?
Max Healthcare Institute's current EBITDA Margin % of 30.53% is 47% above median its 10-year median of 20.74. Over the past 10 years, this metric has ranged from a low of 9.48 to a high of 31.17. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Max Healthcare Institute's value of 30.53% is 198.3% above this industry median. Based on the distribution chart, Max Healthcare Institute ranks #73 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Max Healthcare Institute has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Max Healthcare Institute's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Max Healthcare Institute ranks #73 out of 666 companies for EBITDA Margin %. This places Max Healthcare Institute in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Max Healthcare Institute's value of 30.53% is 198.3% above this benchmark. Historically, Max Healthcare Institute's own EBITDA Margin % has ranged from 9.48 to 31.17 over the past decade. While the company's 10-year median is 20.74 vs. the industry median of 10.24, Max Healthcare Institute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Max Healthcare Institute's current EBITDA Margin % of 30.53% is 198.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Max Healthcare Institute and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Max Healthcare Institute's current EBITDA Margin % is 30.53%, which is 47% above median its own 10-year median of 20.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Max Healthcare Institute stock overvalued right now?
Based on GuruFocus' analysis, Max Healthcare Institute (NSE:MAXHEALTH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,420.80, compared to a current price of ₹1,129.25 — trading 20.5% below its estimated fair value. The current EBITDA Margin % is 30.53%, which is 47% above median its 10-year median of 20.74 and 198.3% above the Healthcare Providers & Services industry median of 10.24. Max Healthcare Institute's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Max Healthcare Institute (NSE:MAXHEALTH), the current EBITDA Margin % is 30.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Max Healthcare Institute (NSE:MAXHEALTH) Overvalued in 2026?
Based on GuruFocus' analysis, Max Healthcare Institute stock appears to be undervalued.
The current stock price of ₹1,129.25 is trading 20.5% below its estimated GF Value™ of ₹1,420.80.
GuruFocus considers Max Healthcare Institute to be Modestly Undervalued.
Key valuation signals for NSE:MAXHEALTH:
EBITDA Margin %: 30.53% (47% above median its 10-year median of 20.74)
GF Value™: ₹1,420.80 vs. price of ₹1,129.25 (20.5% below fair value)
Industry Position: 198.3% above the Healthcare Providers & Services median (#73 of 666)
No single metric tells the full story. See the NSE:MAXHEALTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Max Healthcare Institute Ltd is a health care service provider. The company's facilities include third-party healthcare providers with whom the company has entered long-term service contracts for providing clinical, radiology, and pathology services. Its hospitals provide the full range of services through its Outpatient, Day Care, Emergency Room, and In-Patient departments to accommodate medical specialties such as orthopedics, internal medicine, general surgery, cardiac sciences, oncology, neurosciences, and obstetrics, as well as diagnostics. The group derives revenue from India.
90GF Score
Get the complete analysis for NSE:MAXHEALTH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MAXHEALTH has been successfully added to your 
